Inactive Instrument

Fuss Brands Corp.

Equities

FBDS

US16890Y1047

Fuss Brands Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023

September 05, 2023 at 11:36 pm IST

Fuss Brands Corp. reported earnings results for the third quarter and nine months ended July 31, 2023. For the third quarter, the company reported net loss was USD 0.115827 million compared to USD 0.019657 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the nine months, net loss was USD 0.362684 million compared to USD 0.06982 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.

Latest news about Fuss Brands Corp.

Fuss Brands Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	18/03	CI
Fuss Brands Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	05/02	CI
Fuss Brands Corp. Announces Resignation of Issamar Ginzberg as Chief Executive Officer	12/01	CI
Fuss Brands Corp. Announces Board Changes	12/01	CI
Fuss Brands Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	05/23/05	CI
Fuss Brands Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	13/23/13	CI
Fuss Brands Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023	09/23/09	CI
Fuss Brands Corp. Reports Earnings Results for the Full Year Ended October 31, 2022	27/23/27	CI
Fuss Brands Corp. Receives Purchase Order from Roomwagon, LLC	27/23/27	CI
Fuss Brands Corp. Auditor Raises 'Going Concern' Doubt	27/23/27	CI
Fuss Brands Corp. announced that it has received $0.078 million in funding	18/23/18	CI
Fuss Brands Corp. Signs Licensing Agreement with Anyvention Ltd. to Acquire Intellectual Property Rights	04/22/04	CI
Fuss Brands Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	08/22/08	CI
China Botanic Pharmaceuticals Inc. has Changed its Name to Fuss Brands Corp	22/22/22	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	08/22/08	CI
Fuss Brands Corp. announced a financing transaction	04/22/04	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	25/22/25	CI
China Botanic Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt	16/21/16	CI
China Botanic Pharmaceutical Inc. Announces Management Changes	25/21/25	CI
China Botanic Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended January 31, 2021	15/21/15	CI
China Botanic Pharmaceutical Inc. Announces Executive Appointments	17/21/17	CI
China Botanic Pharmaceutical Inc. Appoints David Lazar as Chief Executive Officer	17/21/17	CI
China Botanic Pharmaceutical Inc. Appoints David Lazar as Chief Financial Officer	17/21/17	CI
China Botanic Pharmaceutical Inc. Appoints Jack Zhao as Independent Director, Chairman of the Audit Committee, and Member of Compensation Committee and Nomination Committee	24/13/24	CI
Zack Pan Resigns as Chair of the Audit Committee, Member of the Compensation Committee and the Nominations Committee, and as Director of China Botanic Pharmaceutical Inc., Effective December 24, 2012	28/12/28	CI

Chart Fuss Brands Corp.

Duration

Period

More charts

Company Profile

Fuss Brands Corp. is a shell company. The Company intends to explore and identify business opportunities within the United States, including an acquisition of an operating entity through a reverse merger, asset purchase, or similar transaction. The Company has no operations and has not generated any revenue.

Sector

More about the company